Diagnos Laboratorium Utama Targetkan Kinerja Naik 20 percent di 2024 - KONTAN
| DGNS Stock | IDR 159.00 3.00 1.85% |
About 62% of Diagnos Laboratorium's investor base is looking to short. The analysis of current outlook of investing in Diagnos Laboratorium Utama suggests that many traders are alarmed regarding Diagnos Laboratorium's prospects. Diagnos Laboratorium's investing sentiment shows overall attitude of investors towards Diagnos Laboratorium Utama.
Diagnos |
Diagnos Laboratorium Utama Targetkan Kinerja Naik 20 percent di 2024 KONTAN
Read at news.google.com
 |
Diagnos Laboratorium Fundamental Analysis
We analyze Diagnos Laboratorium's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagnos Laboratorium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagnos Laboratorium based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Diagnos Laboratorium is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Diagnos Laboratorium Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Diagnos Laboratorium stock to make a market-neutral strategy. Peer analysis of Diagnos Laboratorium could also be used in its relative valuation, which is a method of valuing Diagnos Laboratorium by comparing valuation metrics with similar companies.
Peers
Diagnos Laboratorium Related Equities
| HEAL | Medikaloka Hermina | 8.07 | ||||
| DMMX | Digital Mediatama | 1.97 | ||||
| BMHS | Bundamedik Tbk | 0.88 | ||||
| IRRA | Itama Ranoraya | 0.45 | ||||
| PRDA | Prodia Widyahusada | 1.06 |
Other Information on Investing in Diagnos Stock
Diagnos Laboratorium financial ratios help investors to determine whether Diagnos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagnos with respect to the benefits of owning Diagnos Laboratorium security.